fbpx
Jason McKeown, CEO of Neurovalens and Tina Lai Liedtky, newly appointed party to board of directors

Neurovalens appoints US medical device expert to key non-exec board role

Global health tech company Neurovalens has announced the appointment of an experienced US medical devices expert who will bring invaluable expertise to its board as the business prepares to enter its next phase of growth.  

 

Tina Lai Liedtky, President of the Clinical Diagnostics Division at Massachusetts-headquartered scientific services giant Thermo Fisher Scientific, has been appointed to a non-executive position on Neurovalens’ board of directors.

 

Based in Belfast and San Diego, Neurovalens is a global health-tech company that creates non-invasive neurostimulation products used to solve some of the world’s greatest health challenges, including diabetes, obesity, anxiety and insomnia. The vision of the company is to use technology that can influence the brainstem and hypothalamus in a non-invasive way to cure or treat neurological diseases without the need for implanted electrodes.

 

Tina has an extensive history in the field of medical devices with an emphasis on neurotechnology and treatment of diabetes. As President of Clinical Diagnostics at Thermo Fisher Scientific, she currently oversees a $1bn division with over 2,300 employees. She has previously held commercial leadership roles for Abbott Diabetes Care, commercializing a breakthrough continuous glucose monitoring device for diabetes management, and Abbott Rapid Diagnostics, managing their Cardiometabolic business with the world’s leading point-of-care HbA1c platform.

 

Tina’s prior experience also includes roles at Boston Scientific and Covidien (Medtronic) where her focus was on opportunities to expand indications for the implanted neuromodulation technology in the areas of headache and Parkinson’s disease, and in the area of neurovascular intervention.

 

Tina Lai Liedtky said: “This is an exciting time for Neurovalens as the company expands its platform technology to address Type 2 Diabetes and PTSD. The ambitious target of achieving multiple FDA approvals will allow them to tackle some of the most challenging healthcare issues across the world. I look forward to working closely with Neurovalens’ leadership team as they press forward with their commercial strategy.

 

Dr Jason McKeown, Chief Executive of Neurovalens, added: ‘I am delighted to welcome Tina to our board of directors at this very important time in Neurovalens’ growth. Tina’s inspiring knowledge of the medical device sector and her passion for innovation will be key assets as we look to achieve a range of medical device approvals and commercialize our technology in both the metabolic and neurological areas.”

 

Neurovalens last year raised £5.2m in funding from UK and Irish investors, which has been used to expand existing clinical trials, fund new trials and develop the application of its technology to the treatment of a wider range of conditions. 

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Stay updated

Keep up to date with all the latest news from Digital DNA HQ